Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 6/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | HCK | P08631 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17182866 | 0.80 | PDE4D (0.40) | PIM1GSK3BCHEK1CCNA2CDK2 | |
| SCHEMBL15719043 | 0.78 | TTK (0.43) | TTKMAPK14GSK3BCYP3A4CHEK1 | |
| SCHEMBL17182886 | 0.77 | TTK (0.43) | TTKMAPK14GSK3BCYP3A4 | |
| SCHEMBL17190213 | 0.74 | TTK (0.77) | TTKCYP3A4 | |
| SCHEMBL17182858 | 0.74 | TTK (0.56) | TTKCYP3A4 | |
| SCHEMBL17182803 | 0.73 | TTK (0.41) | TTKMAPK14CYP3A4 | |
| SCHEMBL17190192 | 0.73 | TTK (0.41) | TTKMAPK14CYP3A4 | |
| SCHEMBL17182923 | 0.71 | TTK (0.38) | TTKGSK3BCYP3A4 | |
| SCHEMBL17182936 | 0.71 | TTK (0.38) | TTKGSK3BCYP3A4 | |
| SCHEMBL17182806 | 0.70 | TTK (0.40) | TTKMAPK14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-2920181-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIV HEALTH NETWORK (CA) | 2019-01-09 | — | — | EP | disclosed |
| EP-2920181-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIV HEALTH NETWORK (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-10106545-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-23 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | TTK 3149/4885PIM1 896/4885MAPK14 840/4885 |
| US-10570143-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | TTK 3149/4885PIM1 896/4885MAPK14 840/4885 |
| US-10106545-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | TTK 3015/4885PIM1 822/4885MAPK14 1295/4885 |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | TTK 3015/4885PIM1 822/4885MAPK14 1295/4885 |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | TTK 3015/4885PIM1 822/4885MAPK14 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.